Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PD 155080

Known as: PD-155080 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
We have documented the effects of long-term endothelin receptor antagonism on intracellular Ca2+ regulation and Ca2+ regulatory… Expand
2002
2002
We studied the effect of long-term treatment with the oral endothelin (ET) ET(A) antagonist 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4… Expand
1999
1999
The endothelin system is highly activated during endotoxin and septic shock. To investigate this matter the selective non-peptide… Expand
Highly Cited
1998
Highly Cited
1998
BACKGROUND Circulating endothelin (ET)-1 is elevated in ischemia/reperfusion and may exert proischemic effects. The aim of the… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1997
Highly Cited
1997
Experiments in cultured vascular smooth muscle cells have shown that angiotensin II (Ang II) stimulates expression of endothelin… Expand
1997
1997
Surgical ablation of renal mass leads to a reduction in kidney function and commonly to the development of hypertension and… Expand
Highly Cited
1996
Highly Cited
1996
The effects of two endothelin (ET) receptor antagonists, PD 155080 (ETA selective) and BQ‐788 (ETB selective), on cardiac… Expand
1996
1996
SummaryThe actions of the endothelins (endothelin-I. endothelin-2 and endothelin-3) are mediated via endothelin-A (EA) and… Expand
1995
1995
Summary: The development of nonpeptide, low molecular weight antagonists with high potency, oral activity, and selectivity is an… Expand